eMedicine Specialties > Cardiology > Valvular Heart Disease

Tricuspid Atresia

Author: Mary C Mancini, MD, PhD, Professor and Chief, Cardiothoracic Surgery, Department of Surgery, Louisiana State University Health Sciences Center-Shreveport
Contributor Information and Disclosures

Updated: Jul 30, 2008

Introduction

Background

Tricuspid atresia is the third most common form of cyanotic congenital heart disease, with a prevalence of 0.3-3.7% in patients with congenital heart disease. The deformity consists of a complete lack of formation of the tricuspid valve with absence of direct connection between the right atrium and right ventricle.

Pathophysiology

Three types of tricuspid atresia are described, depending on the associated relationship of the great vessels. In type I, the great arteries are related normally; in type II, the great arteries are d-transposed; and in type III, the great arteries are l-transposed. The types are further subclassified according to the presence or absence of ventricular septal defects and pulmonary valve pathology.1,2

Other cardiovascular anomalies occur in 15-20% of patients with tricuspid atresia. Most of the associated anomalies relate to transposition of the great vessels. A persistent left superior vena cava anomaly is observed in 15% of patients.

With the absence of the tricuspid valve and no continuity between the right atrium and right ventricle, venous blood returning to the right atrium can exit only by an intra-atrial communication. Because of the obligatory right-to-left shunt at the level of the atria, saturation of the left atrial blood is diminished.

The intracardiac blood flow in tricuspid atresia further depends on the presence or absence of pulmonary arterial pathology. In the absence of pulmonary atresia or pulmonary valve stenosis, the volume of blood to the lungs may be normal with normal oxygenation occurring, resulting in reduced cyanosis. In contrast, with accompanying pulmonary artery or valve stenosis, pulmonary blood flow is reduced, resulting in increased cyanosis.

Pulmonary obstruction occurs most often in patients with tricuspid atresia and normally related great arteries. Patients with d-transposed great arteries and tricuspid atresia generally have unobstructed pulmonary blood flow.

The left ventricle comprises most of the ventricular mass in tricuspid atresia. Because of volume overload (the left ventricle receives all the venous return) and persistent hypoxemia, decreased ventricular function may result in fibrosis, decreased ejection fraction, mitral annular dilatation, and mitral insufficiency.

Frequency

United States

The frequency of tricuspid atresia is 2.9% in autopsy series.

Mortality/Morbidity

Depending on the degree of obstruction and associated anomalies, tricuspid atresia may be lethal at birth. Without repair, the patient rarely survives to adulthood.

Race

No racial predilection is apparent.

Sex

  • Considering all forms of tricuspid atresia, no sexual predilection exists.
  • Males present more frequently with transposed great vessels than females.

Age

The anomaly is congenital and is evident at birth.

Clinical

History

Tricuspid atresia is usually detected in infancy because of presenting cyanosis, congestive heart failure, and growth retardation. Parents provide a history of poor skin coloration (ranging from pallor to frank cyanosis), inability to complete a feeding session, frequent pauses during feeding, and/or frank anorexia. As a result, the infant demonstrates poor growth patterns. Respiratory difficulties are often reported as nasal flaring or muscle retractions. (See eMedicine's Pediatric article Tricuspid Atresia.)

Bacterial endocarditis and brain abscess are common findings in patients with tricuspid atresia and should be considered in children with headaches, seizures, or neurologic deficits.

Physical

  • On inspection, cyanosis is the most common clinical feature of this lesion. The degree of cyanosis depends on the degree of pulmonary blood flow. Infants with associated diminished pulmonary blood flow or infants who depend on a patent ductus arteriosus manifest pronounced cyanosis that worsens as the ductus begins to close. Patients with relatively normal or increased pulmonary blood flow manifest little cyanosis but more pronounced congestive heart failure. For related information, see Medscape's Heart Failure Resource Center.
  • Digital clubbing is common in infants older than 3 months. Jugular venous pulsations and distention are common.
  • The peripheral pulses and pulse volume may be decreased, normal, or increased. The left ventricular impulse is prominent because of volume overload. The apical impulse is hyperdynamic, with displacement to the left of the midclavicular line. A thrill may be felt at the left sternal border in patients with a restrictive ventricular septal defect or pulmonary valve stenosis. The liver may be large and pulsatile.
  • A single first heart sound that may be increased in intensity is usually present. The second heart sound may be single or normally split. The intensity of this sound varies, depending on associated transposition of the great vessels. In normally related great vessels, the second heart sound may be of normal intensity. In transposed great vessels, the second sound is diminished. Cardiac murmurs are present in 80% of patients with tricuspid atresia. A holosystolic murmur that may have a crescendo and decrescendo quality is present, signifying blood flow through the ventricular septal defect. A continuous murmur may be present. Systemic-to-pulmonary arterial collaterals or arterial-to-pulmonary arterial anastomoses surgically created to improve pulmonary blood flow may cause this finding. A murmur of mitral insufficiency may also be present.

Causes

The cause is unknown. Although specific genetic causes of the malformation remain to be determined in humans, the FOG2 gene may be involved in the process. Mice in which the FOG2 gene is knocked out are born with tricuspid atresia. The significance of this finding and its applicability in humans requires further investigation.

More on Tricuspid Atresia

Overview: Tricuspid Atresia
Differential Diagnoses & Workup: Tricuspid Atresia
Treatment & Medication: Tricuspid Atresia
Follow-up: Tricuspid Atresia
Multimedia: Tricuspid Atresia
References

References

  1. Tandon R, Edwards JE. Tricuspid atresia. A re-evaluation and classification. J Thorac Cardiovasc Surg. Apr 1974;67(4):530-42. [Medline].

  2. Weinberg PM. Anatomy of tricuspid atresia and its relevance to current forms of surgical therapy. Ann Thorac Surg. Apr 1980;29(4):306-11. [Medline].

  3. Karamlou T, Ashburn DA, Caldarone CA, et al. Matching procedure to morphology improves outcomes in neonates with tricuspid atresia. J Thorac Cardiovasc Surg. Dec 2005;130(6):1503-10. [Medline].

  4. Airan B, Sharma R, Choudhary SK, et al. Univentricular repair: is routine fenestration justified?. Ann Thorac Surg. Jun 2000;69(6):1900-6. [Medline].

  5. Wong ML, Sim EK, Goh JJ, et al. Bidirectional cavopulmonary anastomosis. Ann Acad Med Singapore. Mar 1999;28(2):237-40. [Medline].

  6. Alexiou C, Delany DJ, Keeton BR, Monro JL. Double-barreled conduit for right atrioventricular connection in tricuspid atresia: a new technique. J Thorac Cardiovasc Surg. Oct 2000;120(4):820-2. [Medline].

  7. Annecchino FP, Fontan F, Chauve A, Quaegebeur J. Palliative reconstruction of the right ventricular outflow tract in tricuspid atresia: a report of 5 patients. Ann Thorac Surg. Apr 1980;29(4):317-21. [Medline].

  8. Behrendt DM, Rosenthal A. Cardiovascular status after repair by Fontan procedure. Ann Thorac Surg. Apr 1980;29(4):322-30. [Medline].

  9. Chopra PS, Rao PS. Corrective surgery for tricuspid atresia: which modification of Fontan- Kreutzer procedure should be used? A review. Am Heart J. Mar 1992;123(3):758-67. [Medline].

  10. Dore A, Somerville J. Right atrioventricular extracardiac conduit as a fontan modification: late results. Ann Thorac Surg. Jan 2000;69(1):181-5. [Medline].

  11. Freedom RM, Hamilton R, Yoo SJ, et al. The Fontan procedure: analysis of cohorts and late complications. Cardiol Young. Oct 2000;10(4):307-31. [Medline].

  12. Gale AW, Danielson GK, McGoon DC, et al. Fontan procedure for tricuspid atresia. Circulation. Jul 1980;62(1):91-6. [Medline].

  13. Haas GS, Hess H, Black M, et al. Extracardiac conduit fontan procedure: early and intermediate results. Eur J Cardiothorac Surg. Jun 2000;17(6):648-54. [Medline].

  14. Amanullah MM, Hasan A, Kirk R. Conduit from hypoplastic right ventricle to pulmonary artery in tricuspid atresia. Asian Cardiovasc Thorac Ann. Jan 2008;16(1):78-80. [Medline].

  15. Anderson RH, Wilkinson JL, Gerlis LM, et al. Atresia of the right atrioventricular orifice. Br Heart J. Apr 1977;39(4):414-28. [Medline].

  16. Durongpisitkul K, Porter CJ, Cetta F et al. Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation. Circulation. Sep 15 1998;98(11):1099-107. [Medline].

  17. Ensley AE, Lynch P, Chatzimavroudis GP, et al. Toward designing the optimal total cavopulmonary connection: an in vitro study. Ann Thorac Surg. Oct 1999;68(4):1384-90. [Medline].

  18. Facchini M, Guldenschuh I, Turina J, et al. Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia. J Cardiovasc Surg (Torino). Aug 2000;41(4):567-70. [Medline].

  19. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. May 1971;26(3):240-8. [Medline].

  20. Franklin RC, Spiegelhalter DJ, Sullivan ID, et al. Tricuspid atresia presenting in infancy. Survival and suitability for the Fontan operation. Circulation. Feb 1993;87(2):427-39. [Medline].

  21. Hager A, Fratz S, Schwaiger M, Lange R, Hess J, Stern H. Pulmonary blood flow patterns in patients with Fontan circulation. Ann Thorac Surg. Jan 2008;85(1):186-91. [Medline].

  22. Hess J. Long-term problems after cavopulmonary anastomosis: diagnosis and management. Thorac Cardiovasc Surg. Apr 2001;49(2):98-100. [Medline].

  23. Humes RA, Porter CJ, Mair DD, et al. Intermediate follow-up and predicted survival after the modified Fontan procedure for tricuspid atresia and double-inlet ventricle. Circulation. Sep 1987;76(3 Pt 2):III67-71. [Medline].

  24. Kirklin JK, Blackstone EH, Kirklin JW, et al. The Fontan operation. Ventricular hypertrophy, age, and date of operation as risk factors. J Thorac Cardiovasc Surg. Dec 1986;92(6):1049-64. [Medline].

  25. Lee CN, Schaff HV, Danielson GK, et al. Comparison of atriopulmonary versus atrioventricular connections for modified Fontan/Kreutzer repair of tricuspid valve atresia. J Thorac Cardiovasc Surg. Dec 1986;92(6):1038-43. [Medline].

  26. Ovroutski S, Ewert P, Alexi-Meskishvili V, et al. Comparison of somatic development and status of conduit after extracardiac Fontan operation in young and older children. Eur J Cardiothorac Surg. Dec 2004;26(6):1073-9. [Medline].

  27. Park SC, Neches WH, Mullins CE, et al. Blade atrial septostomy: collaborative study. Circulation. Aug 1982;66(2):258-66. [Medline].

  28. Rao PS. Tricuspid atresia. Mount Kisco, NY: Futura Publishing Co; 1982:13-24.

  29. Sanders SP, Wright GB, Keane JF, et al. Clinical and hemodynamic results of the Fontan operation for tricuspid atresia. Am J Cardiol. May 1982;49(7):1733-40. [Medline].

  30. Sano S, Ishino K, Kawada M, et al. Staged biventricular repair of pulmonary atresia or stenosis with intact ventricular septum. Ann Thorac Surg. Nov 2000;70(5):1501-6. [Medline].

  31. Sarkozy A, Conti E, D'Agostino R, et al. ZFPM2/FOG2 and HEY2 genes analysis in nonsyndromic tricuspid atresia. Am J Med Genet A. Feb 15 2005;133(1):68-70. [Medline].

  32. Stefanelli G, Kirklin JW, Naftel DC, et al. Early and intermediate-term (10-year) results of surgery for univentricular atrioventricular connection ("single ventricle"). Am J Cardiol. Oct 1 1984;54(7):811-21. [Medline].

  33. Takeda M, Shimada M, Sekiguchi A, Ishizawa A. Long-term results of the fenestrated Fontan operation. Progress of patients with patent fenestrations. Jpn J Thorac Cardiovasc Surg. Sep 1999;47(9):432-9. [Medline].

  34. Tongsong T, Sittiwangkul R, Wanapirak C, Chanprapaph P. Prenatal diagnosis of isolated tricuspid valve atresia: report of 4 cases and review of the literature. J Ultrasound Med. Jul 2004;23(7):945-50. [Medline].

  35. Tzifa A, Gauvreau K, Geggel RL. Factors associated with development of atrial septal restriction in patients with tricuspid atresia involving the right-sided atrioventricular valve. Am Heart J. Dec 2007;154(6):1235-41. [Medline].

  36. van Doorn CA, de Leval MR. The Fontan operation in clinical practice: indications and controversies. Nat Clin Pract Cardiovasc Med. Mar 2005;2(3):116-7. [Medline].

  37. van Son JA, Mohr FW, Hambsch J, et al. Conversion of atriopulmonary or lateral atrial tunnel cavopulmonary anastomosis to extracardiac conduit Fontan modification. Eur J Cardiothorac Surg. Feb 1999;15(2):150-7; discussion 157-8. [Medline].

Further Reading

Keywords

tricuspid atresia, TA, cyanotic congenital heart disease, tricuspid valve, right atrium, right ventricle, ventricular septal defects, atrial septal defects, cyanosis, hypoxemia, congestive heart failure, bacterial endocarditis, brain abscess, digital clubbing, polycythemia, Blalock-Taussig shunt, Glenn shunt, Fontan procedure, Fontan operation, transposition of the great vessels, pulmonary obstruction, d-transposed great arteries, FOG2 gene, polycythemia

Contributor Information and Disclosures

Author

Mary C Mancini, MD, PhD, Professor and Chief, Cardiothoracic Surgery, Department of Surgery, Louisiana State University Health Sciences Center-Shreveport
Mary C Mancini, MD, PhD is a member of the following medical societies: American Association for Thoracic Surgery, American College of Surgeons, American Surgical Association, Phi Beta Kappa, Society of Thoracic Surgeons, and Southern Surgical Association
Disclosure: Nothing to disclose.

Medical Editor

Park W Willis IV, MD, Sarah Graham Distinguished Professor of Medicine and Pediatrics, University of North Carolina at Chapel Hill School of Medicine
Park W Willis IV, MD is a member of the following medical societies: American Society of Echocardiography
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Ronald J Oudiz, MD, FACP, FACC, Associate Professor of Medicine, Division of Cardiology, The David Geffen School of Medicine at UCLA; Director, Liu Center for Pulmonary Hypertension, LA Biomedical Research Institute at Harbor-UCLA Medical Center
Ronald J Oudiz, MD, FACP, FACC is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Heart Association, and American Thoracic Society
Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Encysive Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria; Lilly Grant/research funds Clinical Trials + honoraria; LungRx  Clinical Trials + honoraria

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD, Professor and Executive Vice Chairman, Department of Medicine, University of Texas Health Science Center at San Antonio
Richard A Lange, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, and Association of Subspecialty Professors
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.